A Study of LY3015014 in Participants With High Cholesterol
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to define the amount and duration of cholesterol lowering and to
assess the safety and tolerability of different dose regimens of LY3015014 in participants
with high cholesterol. The study will also investigate how the body processes the drug and
how the drug affects the body. Participants will remain on a stable diet and will continue
taking cholesterol-lowering medications (statins with or without ezetimibe). After signing
the informed consent document, the participant will complete a screening/run-in period that
will last at most 8 weeks. Then, the treatment period will last approximately 16 weeks. After
the treatment period, the participants will complete a follow-up period lasting approximately
8 weeks for a total study duration ranging from approximately 25 to 32 weeks.